Feb 9, 2020 10:00 am EST
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
Adverum Biotechnologies NASDAQ:
02/17/20 3:07 PM EST
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Feb 14 2020
Summary ToggleAdverum Biotechnologies Announces Closing of $150 Million Public Offering of Common Stock
- Feb 11 2020
Summary ToggleAdverum Biotechnologies Announces Pricing of Public Offering of Common Stock
- Feb 10 2020
Summary ToggleAdverum Biotechnologies Announces $100 Million Public Offering of Common Stock
- Feb 8 2020
Summary ToggleAdverum Biotechnologies Reports New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at Angiogenesis, Exudation, and Degeneration 2020
|Summary Toggle Mar 3, 2020 at 8:40 AM EST||
|Summary Toggle Feb 25, 2020 at 9:00 AM EST||
New York, NY